I agree - as Yenom23 eluded to earlier in post # 31769779, the...

I agree - as Yenom23 eluded to earlier in post # 31769779, the growth potential for the SP could be extraordinary over the coming months.

The company is gradually being de-risked, subject to a successful release and launch of MachII - but most importantly with the required manufacturing, distribution and sales agreements that should come. in part at least, with the release, followed by further expansion once the inevitable manufacturing/supply issues are dealt with.

Focus being on three initial markets is smart IMO, but demand and expansion will/should come quickly on anecdotal feedback and reviews by users and medico's.

Glad to have topped up - and very much happier following the recent 100-day update.

I have stated on more than one occasion that Respiri could easily join the ranks of darling "Blue Chip" tickers on the ASX 100, or perhaps 50, in a few years. Potentially a similar story to Cochlear.

Cheers

Cabe